You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

11 search results for: neuroimmune mechanisms

<b>Neuroimmune</b> Axis in Atopic Dermatitis

expert video

Neuroimmune Axis in Atopic Dermatitis

8 min

Dermatology

A review of the neuroimmune mechanisms and changes to skin barrier that result in itch in AD.

A Triad of Interacting <b>Mechanisms</b> Driving the Pathophysiology of AD, Asthma, CRSwNP, and EoE

Infographic

A Triad of Interacting Mechanisms Driving the Pathophysiology of AD, Asthma, CRSwNP, and EoE

5 min

Type 2 Inflammation

Discover how barrier dysfunction, neuroimmune dysregulation, and type 2 inflammation contribute to the pathophysiology of various diseases

expert video

Skin Barrier, Neuroimmune Axis, and Type 2 Inflammation in Atopic Dermatitis

69 min

Dermatology

Presentations from the ADVENT symposium at the ISID 2023 meeting on the skin barrier, neuroimmune axis, and type 2 inflammation in atopic dermatitis.

Skin Barrier, <b>Neuroimmune</b> Axis, and Type 2 Inflammation in Atopic Dermatitis - Q&As

expert video

Skin Barrier, Neuroimmune Axis, and Type 2 Inflammation in Atopic Dermatitis - Q&As

11 min

Dermatology

Expert insights on the plasticity of inflammation, atopic dermatitis endotypes, and dysbiosis – Audience Q&A from the ADVENT symposium at ISID 2023.

Immune System, Microbiome and <b>Neuroimmune</b> Crosstalk in the Skin: Implications for AD

expert video

Immune System, Microbiome and Neuroimmune Crosstalk in the Skin: Implications for AD

18 min

Dermatology

The role of dysbiosis in the propagation of type 2 inflammation and itch in atopic dermatitis – a presentation from the ADVENT symposium at ISID 2023.

expert video

Normalizing Skin Barrier by Inhibiting IL-4 & IL-13, or IL-13 Alone

5 min

Dermatology

Dr. Ramien explores how advanced systemic therapies may modify atopic dermatitis pathomechanisms including skin barrier dysfunction, and neuroimmune dysregulation

expert video

Role of Type 2 Inflammation in Chronic Inflammatory Diseases

15 min

Dermatology

Type 2 inflammatory mechanisms and key type 2 cytokines in the pathogenesis of atopic dermatitis – Presentation from the ADVENT symposium at ISID 2023

expert video

Type 2 Inflammation in AD Manifestations in Skin and Body

6 min

Dermatology

Dr. Ramien discusses the role of type 2 inflammation in the pathophysiology of atopic dermatitis, and highlights the association of atopic dermatitis with systemic diseases and comorbidities.

interactivity

Expert Case Series: What is the Role of Type 2 Inflammation in Skin Barrier Dysfunction Commonly Observed in Atopic Dermatitis?

10 min

Dermatology

Gain insights with Prof. Lisa Beck: Explore the link between skin barrier dysfunction and type 2 inflammation in atopic dermatitis.

expert video

Importance of Barrier Dysfunction in Driving AD Pathophysiology

22 min

Dermatology

The impact of type 2 inflammation on components of the skin barrier driving atopic dermatitis – a presentation from the ADVENT symposium at ISID 2023.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: IndiaChange country/region